[Differences in health-related quality of life between male and female hemodialysis patients]. / Diferencias en la calidad de vida relacionada con la salud entre hombres y mujeres en tratamiento en hemodíalisis.

BACKGROUND: Previous studies in renal patients have reported that women perceive a lower health-related quality of life (HRQOL) than men: however, these studies have been carried out without taking into account the gender-related differences shown in general population samples. The aims of the present study are: a) to define the HRQOL dimensions in which there are differences between men and women on chronic hemodialysis (HD), correcting then the differences on the generic dimensions by means of standardization by age and gender of the obtained scores, using Spanish normative data, and b) to identify the variables that cause these possible gender-related differences on HRQOL. METHODS: A cross-sectional multi-center study was carried out with 152 patients (69 men and 83 women) receiving HD treatment in 43 Spanish centers, using the KDQOL-SF to evaluate their HRQOL. The generic KDQOL-SF scores were standardized by age and gender using Spanish normative data. Sociodemographic, clinical and psychosocial variables were also collected on each patient. A MANOVA was carried out to study the variables associated with the gender-related differences on HRQOL. The sociodemographic, clinical and psychosocial variables showing significant differences between men and women in the previous univariate analysis were entered as covariates. RESULTS: The KDQOL-SF scores showed statistically significant differences between men and women in four scales: physical functioning, emotional role limitation, social function and emotional well-being. In contrast, standardized scores showed no differences between men and women in the profile or degree of HRQOL impairment. Although statistically significant gender-related differences were shown in educational level, employment, haemoglobin, Kt/V, trait anxiety and depressive symptoms, only the last two variables showed an independent effect on the differences in HRQOL. CONCLUSION: Impaired HRQOL in women on HD reflects the gender-related differences that are also shown in the general population, and they are related to the higher prevalence of trait anxiety and depressive symptoms in women.

The influence of extracellular fluid volume on serum proteins in peritoneal dialysis patients.

AIM: Patients on peritoneal dialysis (PD) often present a deficit of serum protein and especially of albumin, due to its loss through the peritoneum and some others factors. Serum albumin is a marker of survival, of nutritional status and is changed in inflammation in renal failure. Correction of the albumin level is difficult and needs a dietary or other supplementation. Some suspicions exist that a reduction exist that a reduction in overhydration in PD patients may improve serum proteins, particularly albumins. The study tries to prove or to deny the thesis, investigating 27 PD patients (cycler PD, CPD) during 6 weeks. METHODS: Body weight, blood pressure, total serum protein, albumin, C-reactive protein, 24-h urine and volume of the dialysate solution were measured at the first and the final week. The extracellular fluid volume was evaluated by multiple-frequency bioelectrical impedance. Dialysis prescription was changed between the 0- and 6-week to increase the daily ultrafiltrate volume (1.00+/-0.87 1 to 1.32+/-0.85 1, p<0.05). RESULTS: There was a significant reduction in body weight (p<0.001), extracellular fluid volume (p<0.001), systolic blood pressure (p<0.001), diastolic blood pressure (p<0.01). Serum albumin increased significantly (p<0.01), there was a trend to augmentation of total protein and C-reactive protein did not change. CONCLUSIONS: The study suggests that overhydration has only a light influence on total serum protein, but impacts significantly the serum albumin level and blood pressure as well. The reduction in body weight can be a helpful way to overcome the hypoalbuminemia and hypertension i.e. to improve the survival time of patients on continuous ambulatory peritoneal dialysis.

El índice de respuesta a la eritropoyetina (IRE) es un buen marcador de adecuación en diálisis / No disponible

No disponible

Chronic kidney disease: why is current management uncoordinated and suboptimal?

Morbidity and mortality associated with chronic kidney disease (CKD) is higher than that of the normal population, and the incidence of end-stage renal disease (ESRD) continues to increase. Several factors contribute to the uncoordinated and suboptimal management of CKD, including the attitude and behaviour of nephrologists, referring physicians and patients, and economic constraints on healthcare systems. Late referral of at-risk patients to specialist care is an area of particular concern, as this denies nephrologists adequate opportunity to prevent progression of CKD and associated complications such as anaemia. Due to the ageing population and advances in technology, the costs of treating CKD and ESRD continue to escalate and represent another barrier to the delivery of optimal care. Optimizing the care provided to CKD patients requires a coordinated approach to the management of the condition. Closer collaboration and improved communication across specialities is important for the timely referral of patients and for efficient utilization of available resources. A multidisciplinary approach may facilitate patient identification and improve the management of CKD.

Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis.

BACKGROUND: Recent data have suggested the existence of a relationship between the use of synthetic vascular accesses and increased erythropoietin (Epo) requirements. The present study aimed to evaluate the possible role of the type of vascular access in both Epo and intravenous (i.v.) iron requirements. METHODS: One-hundred-and-seven individuals without recognized causes of Epo resistance, 62 of them undergoing chronic haemodialysis through native arteriovenous fistulae (AVF) and 45 through PTFE grafts, were retrospectively studied (one-year follow-up). Sixty-nine patients, i.e. all but three with a PTFE graft and 27 with native AVF, were taking anti-platelet agents. Doses of i.v. iron and Epo and laboratory parameters were recorded. RESULTS: Erythropoietin and i.v. iron requirements were higher in the patients dialysed through PTFE grafts compared with those with native AVF (Epo: 103.8+/-58.4 vs 81.0+/-44.5 U/kg/week, P=0.025; i.v. iron: 178.9+/-111 vs. 125.9+/-96 mg/month, P=0.01). On a yearly basis, the difference in Epo dose represented a total of 94582+/-16789 U Epo/patient/year. Moreover, the patients with PTFE grafts received more red blood cell transfusions than patients with native AVF (P=0.021). No differences between laboratory, dialysis kinetics, demographic or comorbidity parameters were found. The type of vascular access was the best predictor of the requirement of > or =150 U/kg/week Epo (P=0.03). Even though the patients who received anti-platelet therapy required more i.v. iron (167.5+/-103.6 vs. 114.5+/-101.4 mg/month, P=0.008) but not more Epo (P=NS), the possibility of an accessory role of anti-platelet agents in the increased Epo requirements with PTFE grafts cannot be ruled out. CONCLUSIONS: The use of a PTFE graft and anti-platelet drugs represents a previously undescribed association related to higher Epo and i.v. iron requirements. The association described herein adds new arguments to the debate concerning the choice of vascular access in chronic haemodialysis patients.

Quality of life in end-stage renal disease patients.

Health-related quality of life (QOL) refers to the measure of a patient's functioning, well-being, and general health perception in each of three domains: physical, psychological, and social. Along with survival and other types of clinical outcomes, patient QOL is an important indicator of the effectiveness of the medical care they receive. QOL of patients with end-stage renal disease is influenced by the disease itself and by the type of replacement therapy. Numerous studies have identified the effect of such factors as anemia, age, comorbidity, and depression on QOL. Most of these factors appear during the predialysis period, and the adequate management of some of them could influence patient outcomes. Among replacement therapies, transplantation appears to give the best QOL for large groups of patients. No conclusive data exist to prove differences in QOL between hemodialysis patients and peritoneal dialysis patients. In the case of elderly patients or those with a high degree of comorbidity, the best treatment option should be assessed in each individual case, taking all possible factors into account. Finally, it has been proven that physical and mental function are inversely correlated with the risk for hospitalization and mortality.

[Pre-occupying increase in diabetes as cause for terminal kidney failure. Evaluation of treatment strategies]. / Preocupante incremento de la diabetes como causa de insuficiencia renal terminal. Evaluación del tratamiento sustitutivo.

OBJECTIVE: To study the incidence, prevalence, treatment modalities and prognosis of diabetic patients on renal replacement therapy. MATERIAL: We studied all end-stage renal failure (ESRF) diabetic patients on renal replacement therapy in "Area Sanitaria 1" in Madrid from 1978 to 1998. RESULTS: Diabetes mellitus has become the leading cause of ESRF in our health area of Madrid, 30% of all causes of ESRF. Incidence of diabetics beginning RRT was 33.3 per million population (pmp) in 1998, while in 1993-94 diabetes was 15% and 21 pmp, respectively, table 1. The proportion of diabetics on RRT has increased from 7.4% 1986 to 12.7% 1998. The prevalence of diabetics on RRT in 1998 was 135 pmp, with an overall prevalence of 1054 pmp. At the mean time, the proportion between incident diabetics type 2/diabetics on RRT has increased from 15% in 1987-88, to 54% in 1993-94 and to 81% in 1997-98, consequently, mean age of diabetic patients at beginning RRT has increased from 47 years before 1988, 58 in 1989-90, 61 in 1993-94, 62 in 1995-96 and 63 in 1997-98 (Table I). We studied 182 diabetics admitted for renal replacement therapy, 106 males and 76 females, 105 were diabetics type 1 and 77 type 2. Their mean age at RRT beginning was 57.12 years (SD). Hemodialysis (HD) was the first modality of treatment for 128 (70%) diabetics and CAPD for 54. Seventy out of 128 patients on HD were dialyzed in the Hospital Unit, 40% on AFB (acetate free biofiltration) and 58 in two Satellite Units, that means a higher proportion of diabetics on CAPD and on HD in Hospital Unit. Diabetics allocated to CAPD were 5 years, as mean, younger than patients allocated to HD (p < 0.01) and the proportion of diabetes type 1 was higher in CAPD (72%) than in HD (51%), p 0.05. During the mean follow-up period (51.45 months) 79 patients changed their treatment modality and 45 of them received a kidney allogral. Relative risk of drop-out was higher in CAPD technique when compared to HD. Clinical complications were frequently observed: ocular (77%), cardiovascular (Myocardial infarction 1.7%), acute cerebrovascular disease (21%) and distal angiopathy (35%), 10% amputee. At December of 1998, 89 patients were dead. Cardiovascular and cerebrovascular diseases (29%) and Infections (27%) were the two most frequent causes of death. Unknown-origin deaths represent 19% of all deaths. The overall survival (Kaplan Meier) was 92%, 80%, 72%, 61% and 54% at 1, 2, 3, 4 and 5 years, respectively (57 patients completed last period). Survival was better on HD than on CAPD, but without statistical significance, although the significant difference in age and in proportion of diabetes type 2 between both groups. Data analysis estimated by Cox proportional hazards regression shows that younger age and ki,r transplantation had a positive independent effect on survival, whik clinical distal angiopathy had important negative effect on survival. CONCLUSIONS: Diabetes mellitus has become the leading case of ESRF in our health area of Madrid. Young age and kidney transplantation had a positive independent effect on survival, while clinical distal angiopathy had important negative effect.

Prevalence of hypertension in renal disease.

BACKGROUND: Hypertension (HTN) is very frequent in patients with renal disease and its prevalence increases as renal failure progresses. METHODS: We studied the prevalence of HTN in 1921 patients with different nephropathies. Patients on dialysis and renal transplant patients were not included in the study. HTN was defined as SBP>140 and/or DBP>90 mmHg, or requiring antihypertensive therapy. RESULTS: The prevalence of HTN in the total group of patients with renal diseases was 60.5%, but this prevalence varied widely depending upon the type of underlying nephropathy. The prevalence of HTN was practically universal in patients with renal vascular disease (93%) and in patients with established diabetic nephropathy (87%), and 74% of the patients with polycystic kidney disease, 63% of the patients with chronic pyelonephritis and 54% of the patients diagnosed with glomerulonephritis were hypertensive. The prevalence of HTN in patients with renal insufficiency (80%) is significantly higher than that in patients without renal insufficiency (43% P<0.001). In a multiple logistic regression analysis, the independent risk factors defining HTN in renal patients were: renal failure, age, the presence of diabetes, hypertriglyceridaemia and proteinuria. Antihypertensive treatment consisted of diet alone in 4% of the patients, one drug in 45%, two drugs in 36%, three medications in 13% and more than three drugs in 2.5%. The angiotensin-converting enzyme (ACE) inhibitors were the most frequently prescribed drug (39% of the patients treated in monotherapy) followed by calcium channel blockers (27%), diuretics (18%) and beta-blockers (9%). The most common combined therapy was a diuretic plus an ACE inhibitor. The percentage of patients with BP controlled according to current recommendations for renal patients (BP<130/85) was very low; SBP in only 49% and DBP in 24%. Control of both was only achieved in 10% of the patients. CONCLUSIONS: There is a high prevalence of HTN in renal patients, which depends on the type of nephropathy and the degree of renal failure. Other independent risk factors for HTN in patients with renal disease are: advanced age, the presence of diabetes, hypertriglyceridaemia and the severity of proteinuria. BP control in renal patients is quite poor and should be improved to reduce progression of the renal disease.

Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.

BACKGROUND: The severity of proteinuria is the main predictive factor in the progression of renal failure in chronic nephropathies. Therefore, action aimed at reducing proteinuria should be a priority in the treatment of these patients. Various antihypertensive drugs, in particular the angiotensin-converting enzyme inhibitors (ACEIs), have a greater antiproteinuric effect, although it is difficult to establish whether this is due only to their effect on arterial blood pressure (BP) or to other mechanisms associated with blockade of the renin-angiotensin system (RAS). METHODS: The evolution of proteinuria after two successive treatment periods was studied prospectively for 2 years in 22 patients with chronic glomerulonephritis. In period I, which lasted for 12 months, BP was strictly controlled (<125/75 mmHg) and the patients received random and double-blind treatment with a beta-blocker (betaB), atenolol; a non-dihydropyridine calcium channel blocker (CCB), verapamil; an ACEI, trandolapril; or a fixed combination of the latter two. In period II, all of the patients received treatment openly for an additional 12 months with a fixed combination of verapamil+trandolapril at half the dose of the preceding period, to obtain conventional control of BP at <140/90 mmHG: RESULTS: The mean level for basal SBP/DBP was 136+/-14/86+/-7 mmHg, which decreased in period I to 121+/-15/76+/-8 mmHg (P=0.01) and to 124+/-5/78 +/-8 mmHg (P<0.05) at 6 and 12 months of treatment, respectively. There were no differences in the BP reached in the four therapy groups; however, proteinuria only decreased in the patients treated with trandolapril alone or in combination with verapamil. In period II, BP levels rose to 134+/-10/84+/-8 mmHg (P<0.05); this increase in BP was accompanied by an increase in proteinuria in those patients who had received the ACEI alone or in combination in the previous period, while in patients previously treated with a betaB or a CCB, proteinuria decreased, in spite of the increase in BP. CONCLUSIONS: With equal BP control, treatment with the ACEI trandolapril alone, or in combination with a CCB, has a greater antiproteinuric effect than that obtained with other antihypertensive drugs, but this effect is attenuated if BP is not strictly controlled.

Haemodialysis dose, extracellular volume control and arterial hypertension.

Patients with chronic renal failure on periodical dialysis frequently are hypertensive. This frequency has increased in relation to the liberalization of diet and to short dialysis with a high sodium concentration in the dialysate. Although various factors influence the pathogenesis of this type of hypertension, volume overload is the most significant. The achievement of an optimal dry weight is still one of the most difficult and important tasks of a dialysis clinic. The reduction in extracellular volume in haemodialysis implies an improvement in dialysis tolerance. The time factor is one of the principal elements in this control, but it is possible, using other elements, to improve tolerance in 4-5 h sessions and to achieve the proper dry weight associated with normotension in most patients.

Preocupante incremento de la diabetes como causa de insuficiencia renal terminal. Evaluación del tratamiento sustitutivo / Increasing incidence of renal replacement therapy in diabetic patients

Objetivo: Valorar la incidencia, prevalencia, tipo de tratamiento y pronóstico de pacientes diabéticos en tratamiento sustitutivo de la función renal (TSFR).Material: Se estudia a todos los pacientes diabéticos con insuficiencia renal terminal en TSFR en el Área Sanitaria 1 de Madrid desde 1978 hasta 1998.Resultados: La diabetes mellitus se ha convertido en la principal causa de insuficiencia renal terminal en nuestra área sanitaria, constituyendo en la actualidad el 30 por ciento de todas las causas de entrada en TSFR. La incidencia de diabéticos que comenzaron en 1998 TSFR fue de 33,3 pmp, claramente superior a la del periodo 1993-94, 21 pmp. La prevalencia de pacientes diabéticos en TSFR en 1998 fue de 135 pmp, con una prevalencia global de 1054 pmp. Se ha incrementado la proporción de diabéticos tipo 2 con respecto al global de pacientes diabéticos que inician tratamiento sustitutivo, pasando de ser un 15 por ciento en 1987-88 a un 81 por ciento en 1997-98. De manera simultánea, se ha incrementado la edad media de dichos pacientes, pasando de ser 47 años antes de 1988 a 63 años en 1997-98. En total se estudian 182 diabéticos, 106 hombres y 76 mujeres. 105 eran diabéticos tipo 1 y 77 tipo 2, con una edad media al comienzo del TSFR de 57 12 años.La hemodiálisis (HD) fue la primera modalidad de tratamiento en 128 pacientes y la diálisis peritoneal (DP) en 54. Los pacientes que iniciaban DP eran 5 años más jóvenes que los que iniciaban HD, p<0,01, con una mayor proporción de diabéticos tipo 1, 72 por ciento en DP frente a un 51 por ciento en HD, p<0,05. El periodo de seguimiento fue 51 45 meses y durante éste, 79 pacientes cambiaron su modalidad de tratamiento y 45 de los cuales recibieron un trasplante renal (TxR). Las principales complicaciones observadas fueron las oftalmológicas, 77 por ciento, seguidas de la vasculopatía periférica con un 35 por ciento de casos (10 por ciento de amputados). Los accidentes cerebrovasculares y el infarto agudo de miocardio acontecieron en un 21 y 17 por ciento de casos respectivamente. A lo largo del periodo de estudio, murieron 89 pacientes. Las enfermedades cerebro y cardiovasculares constituyeron la causa más frecuente (29 por ciento), seguida de las infecciones (27 por ciento). La supervivencia total fue de 92, 80, 72, 61 y 54 por ciento en el 1, 2, 3, 4 y 5 años respectivamente.La supervivencia fue mejor en HD que en DP, aunque sin alcanzar significación estadística. La menor edad y el TxR eran variables con efecto independiente positivo en la supervivencia, mientras que la vasculopatía distal tenía un importante efecto negativo.Conclusiones: Se comprueba un alarmante aumento en la incidencia de diabéticos tipo 2 que inician TSF. El TxR es la técnica con mejores resultados. (AU)

La diabetes mellitus como causa de insuficiencia renal terminal. ¿Una epidemia del siglo XXI? / Diabetes mellitus as cause of terminal renal failure. An epidemic of the 21st Century?

No disponible

No disponible

Quality of life benefits of early anaemia treatment.

In evaluating outcomes in end-stage renal disease (ESRD), quality of life has become as important as morbidity and mortality. Various instruments are available to analyse patients' perceptions of the physical, psychological and social domains of health. Non-specific instruments, such as the Sickness Impact Profile, the Karnofsky Scale, and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), have been widely used in evaluating quality of life in various chronic diseases including ESRD. The Kidney Disease Quality of Life (KDQOL) questionnaire and other scales have also have been developed specifically for ESRD patients. Several studies have demonstrated a significant improvement in quality of life after initiation of epoetin treatment in both dialysis patients and those with early renal failure. Quality-of-life scores show a strong positive correlation with haemoglobin concentration. Other factors associated with better quality of life are higher socio-economic level and level of education. However, older age, comorbidity, diabetes, female sex, and unemployment have a negative influence on quality of life. In patients not yet on dialysis, quality of life deteriorates as the glomerular filtration rate decreases. The later the patient is referred to a nephrologist, the worse the quality of life. Recent studies show that quality of life is a prognostic factor for survival. Early and effective treatment of anaemia in ESRD patients is essential in maintaining quality of life both before and after initiation of dialysis.